Cargando…

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816912/ https://www.ncbi.nlm.nih.gov/pubmed/33462139 http://dx.doi.org/10.1136/jitc-2020-001235corr1

Ejemplares similares

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Publicado: (2021)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
por: Neelapu, Sattva S, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
por: Emens, Leisha A, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
por: Galsky, Matthew D, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
por: Kelly, Ronan J, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
por: Disis, Mary L, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
por: Greten, Tim F, et al.
Publicado: (2021)

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
por: Boyiadzis, Michael M, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
por: Govindan, Ramaswamy, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
por: Silk, Ann W, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
por: Pavlick, Anna C, et al.
Publicado: (2023)

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
por: Berry, Sneha, et al.
Publicado: (2019)

Correction: Defining current gaps in quality measures for cancer immunotherapy: consensus report from the society for immunotherapy of cancer (SITC) 2019 Quality Summit
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
por: Brahmer, Julie R, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
por: Maus, Marcela V, et al.
Publicado: (2020)

29(th) Annual meeting of the Society for Immunotherapy of Cancer (SITC)
por: Hurwitz, Arthur A, et al.
Publicado: (2015)

Correction: Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
Publicado: (2023)

Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting
por: Stroncek, David F, et al.
Publicado: (2013)

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule
por: Kaufman, Howard L., et al.
Publicado: (2016)

Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016
por: Gulley, James L., et al.
Publicado: (2017)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
por: Kluger, Harriet, et al.
Publicado: (2023)

Preamble to the 2015 SITC immunotherapy biomarkers taskforce
por: Butterfield, Lisa H, et al.
Publicado: (2015)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
por: Rizvi, Naiyer, et al.
Publicado: (2023)

The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer
por: Raval, Raju R, et al.
Publicado: (2014)

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
por: Page, David B., et al.
Publicado: (2015)

Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit
por: Pai, Sara, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
por: Atkins, Michael B, et al.
Publicado: (2023)

Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop
por: Marciscano, Ariel E., et al.
Publicado: (2018)

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
por: Atkins, Michael B, et al.
Publicado: (2022)

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
por: Hu-Lieskovan, Siwen, et al.
Publicado: (2020)

Correction: The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
por: Tawbi, Hussein A, et al.
Publicado: (2023)

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
por: Bedognetti, Davide, et al.
Publicado: (2019)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
por: Puzanov, I., et al.
Publicado: (2017)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)

Correction to: The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition
por: Yamauchi, Chikako, et al.
Publicado: (2021)

Correction to: The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition
por: Inokuchi, Masafumi, et al.
Publicado: (2021)

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
por: Shimoi, Tatsunori, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0c4glfdtmascm4q64ddva99lt9